SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* Wright Joseph (Last) (First) (Middle) 1600 WEST MERIT PARKWAY (Street) SOUTH JORDAN UT 84095 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol MERIT MEDICAL SYSTEMS INC [ MMSI ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) PRESIDENT, INTERNATIONAL
	3. Date of Earliest Transaction (Month/Day/Year) 03/13/2020
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, No Par Value	03/13/2020		M		10,000	A	$13.14	10,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-qualified stock options (right to buy)	$13.14	03/13/2020		M			10,000	07/31/2014(1)	07/31/2020	Common Stock	10,000	$0	0	D
Non-qualified stock options (right to buy)	$12.06							10/04/2015(2)	10/04/2021	Common Stock	25,000		25,000	D
Non-qualified stock options (right to buy)	$17.27							02/13/2016(3)	02/13/2022	Common Stock	10,000		10,000	D
Non-qualified stock options (right to buy)	$16.05							01/28/2017(4)	01/28/2023	Common Stock	20,000		20,000	D
Non-qualified stock options (right to buy)	$28.2							04/14/2018(5)	04/14/2024	Common Stock	25,000		25,000	D
Non-qualified stock options (right to buy)	$44.8							03/02/2019(6)	03/02/2025	Common Stock	25,000		25,000	D
Non-qualified stock options (right to buy)	$55.73							03/01/2020(7)	03/01/2026	Common Stock	30,000		30,000	D
Non-qualified stock options (right to buy)	$37.71							02/26/2021(8)	02/26/2027	Common Stock	16,722		16,722	D
Performance Stock Units	(9)							03/15/2021(10)	03/15/2023(10)	Common Stock	7,955(11)		7,955	D

Explanation of Responses:

1. Becomes exercisable in equal annual installments of 20% commencing on 07/31/2014.

2. Becomes exercisable in equal annual installments of 20% commencing on 10/04/2015.

3. Becomes exercisable in equal annual installments of 20% commencing on 02/13/2016.

4. Becomes exercisable in equal annual installments of 20% commencing on 01/28/2017.

5. Becomes exercisable in equal annual installments of 20% commencing on 04/14/2018.

6. Becomes exercisable in equal annual installments of 20% commencing on 03/02/2019.

7. Becomes exercisable in equal annual installments of 20% commencing on 03/01/2020.

8. Becomes exercisable in equal annual installments of 25% commencing on 02/26/2021.

9. Each performance share unit represents the Company's commitment to issue one share of Merit Medical Systems, Inc. common stock, subject to achievement of performance criteria.

10. If earned by the Reporting Person, the PSUs will be awarded not later than March 15 of the year following the Issuer's achievement of the target level of free cash flow, subject to conditions set forth in the Performance Stock Unit Award Agreement.

11. On February 26, 2020, the reporting person was awarded a target number of performance share units (''PSUs'') pursuant to a Performance Stock Unit Award Agreement by and between the Reporting Person and the Issuer. The actual number of PSUs to be awarded to the Reporting Person will be based upon the Issuer's free cash flow measured against its 2020 financial plan over one, two and three-year periods ending December 31, 2020, 2021 and 2022, respectively, and subject to the Reporting Person's continued employment with the Issuer and the conditions set forth in the Stock Unit Award Agreement.

	/s/ Brian G. Lloyd, Attorney-in-Fact	03/17/2020
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.